<DOC>
	<DOCNO>NCT00145405</DOCNO>
	<brief_summary>The morbidity mortality acromegalic patient closely correspond growth hormone ( GH ) level therefore efficient long-term treatment important . Neurosurgery first choice treatment acromegalic patient . Surgery normalize GH level 80 % patient microadenomas , less 50 % patient macroadenomas respond sufficiently surgery alone . In patient , additional medical therapy therefore need . Somatostatin analogues successfully use treatment acromegaly surgery radiotherapy lead normal GH IGF-I level . Lanreotide Autogel ( LAN ) new formulation lanreotide consist prolonged release aqueous formulation , inject intramuscularly deep subcutaneously every 28 day . Aim The aim present study compare efficacy OCT LAN obtain GH IGF-I level accord 2000 Consensus . Furthermore , want evaluate treatment modality result low possible IGF-I GH level high patient satisfaction .</brief_summary>
	<brief_title>Comparable Effects Lanreotide Autogel Octreotide LAR GH , IGF-I Levels Patient Satisfaction</brief_title>
	<detailed_description>Introduction The morbidity mortality acromegalic patient closely correspond growth hormone ( GH ) level therefore efficient long-term treatment important ( 1 ) . Neurosurgery first choice treatment acromegalic patient . Surgery normalize GH level 80 % patient microadenomas , less 50 % patient macroadenomas respond sufficiently surgery alone ( 1 ) . In patient , additional medical therapy therefore need . Somatostatin analogues successfully use treatment acromegaly surgery radiotherapy lead normal GH IGF-I level ( 2 , 3 , 4 , 5 ) . Lanreotide Autogel ( LAN ) new formulation lanreotide consist prolonged release aqueous formulation , inject intramuscularly deep subcutaneously every 28 day . Aim The aim present study compare efficacy OCT LAN obtain GH IGF-I level accord 2000 Consensus . Furthermore , want evaluate treatment modality result low possible IGF-I GH level high patient satisfaction . Inclusion criterion - patient receive octreotide LAR include ; - new diagnosed patient clinical biochemical acromegaly , medicine therapy indicate ; - long fit exclusion criterion . Exclusion criterion - give consent receive standard information study ; - current malign disease ; - somatostatin analogue intolerance ; - elevation lever enzymes ; - pregnancy . Design The study design randomize cross-over trial . Patients randomize receive either OCT LAN 6 month change opposite therapy 6 month without interruption two therapy Both OCT LAN administer every 28 day . OCT give intramuscularly LAN deep subcutaneously patient ` general practitioner study nurse . At time 0 , 4 , 6 , 10 , 12 month , patient attend clinical evaluation , department Endocrinology , Odense University Hospital . Patients previously treat OCT receive unchanged dos OCT study period OCT dose use calculate LAN dose . The administered OCT dose determine dose necessary obtain normal IGF-I level and/or GH &lt; 1mU/l ( &lt; 0.4 μg/ l ) alternatively high tolerate dose . The LAN dose calculate use OCT dose follow : 10 mg OCT ≈ 60 mg LAN ; 20 mg OCT ≈ 90 mg LAN ; 30 mg OCT ≈ 120 mg LAN . Evaluation program ( 0 , 4 , 6 , 10 , 12 month ) Clinical evaluation : weight , blood pressure , inspection injection site evaluation possible side effect . Analyses : GH IGF-I , prolactin , thyroid hormone , oestrogen , testosterone , LH , FSH , fast plasma glucose glycosylated hemoglobin , liver enzymes level . The study support Beaufor Ipsen Industry technical assistance supply Endocrinology Department , Odense University Hospital . References 1 . Giustina , A. , Barkan , A. , Casanueva , F. F. , Cavagnini , F. , Frohman , L. , Ho , K. , Veldhuis , J. , Wass , J. , Von , Werder K. , Melmed , S. Criteria cure acromegaly : consensus statement.J.Clin.Endocrinol.Metab 2000 85 526-529 2 . Chanson , P. Somatostatin analogs treatment acromegaly : choice possible.Eur.J.Endocrinol . 2000 143 573-575 3 . Cozzi , R. , Dallabonzana , D. , Attanasio , R. , Barausse , M. , Oppizzi , G. A comparison octreotide-LAR lanreotide-SR chronic treatment acromegaly.Eur.J.Endocrinol . 1999 141 267-271 4 . Turner , H. E. , Vadivale , A. , Keenan , J. , Wass , J . A . A comparison lanreotide octreotide LAR treatment acromegaly.Clin.Endocrinol . ( Oxf ) 1999 51 275-280 5 . Verhelst , J . A. , Pedroncelli , A. M. , Abs , R. , Montini , M. , Vandeweghe , M. V. , Albani , G. , Maiter , D. , Pagani , M. D. , Legros , J. J. , Gianola , D. , Bex , M. , Poppe , K. , Mockel , J. , Pagani , G. Slow-release lanreotide treatment acromegaly : study 66 patients.Eur.J.Endocrinol . 2000 143 577-584</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>All patient receive octreotide LAR include ; New diagnose patient clinical biochemical acromegaly , medicine therapy indicate ; As long fit exclusion criterion . Which give consent receive standard information study ; Current malign disease ; Somatostatin analogues intolerance ; Elevation lever enzymes ; Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>somatostatin analogue</keyword>
	<keyword>lanreotide</keyword>
	<keyword>octreotide</keyword>
	<keyword>GH</keyword>
	<keyword>IGF-I</keyword>
	<keyword>injection site</keyword>
</DOC>